Research Opportunities for Medications to Treat Alcohol Dependence: Addressing Stakeholders' Needs
Research Opportunities for Medications to Treat Alcohol Dependence: Addressing Stakeholders' Needs
复制标题
DOI：
10.1111/acer.12193
复制
发表时间：
2014-01-01
影响因子：
3.2
通讯作者：
Fertig, Joanne
中科院分区：
文献类型：
--
作者：
Litten, Raye Z.;Falk, Daniel;Fertig, Joanne
在过去的十年中，治疗酒精依赖的药物的开发取得了重大进展。美国食品和药物管理局已经批准了四种治疗酒精依赖的药物，包括曲安奈德、注射用纳曲酮、氨基己酸酯和二硫胺，还有其他几种药物前景看好。然而，事实仍然是，由于酒精依赖的异质性，这些药物并不是在任何情况下对所有人都有效。此外，临床医生并没有为酒精治疗开这些药物的常规处方。这篇评论提出了一些必须解决的问题，以推动酒精研究领域的发展，并使药物治疗成为问题饮酒的主流治疗方法。这些问题是从不同利益相关者的角度制定的，包括临床医生、患者、监管机构、制药业和第三方付款人。解决这些问题不仅有助于改善治疗，而且，正如进一步描述的那样，还将在未来十年为酒精调查人员打开许多新的研究机会。
During the past decade, significant advances have been made in the development of medications to treat alcohol dependence. Four medications have been approved by the U.S. Food and Drug Administration for treating alcohol dependencenaltrexone, injectable naltrexone, acamprosate, and disulfiramand several others show promise. The fact remains, however, that because of the heterogeneity of alcohol dependence, these medications will not work for all people, in all circumstances. Moreover, clinicians are not routinely prescribing these medications for alcohol treatment. This commentary poses a number of issues that must be addressed in order to advance the alcohol research field and to make medications a mainstream treatment for problematic drinking. These issues are framed from the perspective of the various stakeholders involved, including clinicians, patients, regulatory agencies, the pharmaceutical industry, and third-party payers. Addressing these issues will not only help to improve treatment but, as further described, will also open up many new research opportunities for alcohol investigators in the coming decade.